Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.

@article{Bardy2005AmiodaroneOA,
  title={Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.},
  author={Gust H. Bardy and Kerry Lamont Lee and Daniel B. Mark and Jeanne E. Poole and Douglas L. Packer and Robin Boineau and Michael J. Domanski and Charles Troutman and Jill Anderson and George Johnson and Steven E. McNulty and Nancy E. Clapp-Channing and Linda D Davidson-Ray and Elizabeth S. Fraulo and Daniel P. Fishbein and Richard M. Luceri and John H. Ip},
  journal={The New England journal of medicine},
  year={2005},
  volume={352 3},
  pages={
          225-37
        }
}
  • Gust H. Bardy, Kerry Lamont Lee, +14 authors John H. Ip
  • Published in
    The New England journal of…
    2005
  • Medicine
  • BACKGROUND Sudden death from cardiac causes remains a leading cause of death among patients with congestive heart failure (CHF. [...] Key Method Placebo and amiodarone were administered in a double-blind fashion. The primary end point was death from any cause. RESULTS The median LVEF in patients was 25 percent; 70 percent were in NYHA class II, and 30 percent were in class III CHF. The cause of CHF was ischemic in 52 percent and nonischemic in 48 percent. The median follow-up was 45.5 months. There were 244…Expand Abstract

    Paper Mentions

    INTERVENTIONAL CLINICAL TRIAL
    The ICD-Reality study is a non-commercial, investigator-led, multicenter, prospective, randomized, controlled trial. We aim to determine the effect of CRT-D or CRT-P implantation… Expand
    ConditionsCardiomyopathy, Dilated, 3B
    InterventionDevice
    INTERVENTIONAL CLINICAL TRIAL
    Congestive heart failure (CHF) represents a major health care concern in the United States. Currently, risk stratification of sudden cardiac death and the need for implantable… Expand
    ConditionsDeath, Sudden, Cardiac
    InterventionDevice
    OBSERVATIONAL CLINICAL TRIAL
    The "EUropean Comparative Effectiveness Research to assess the use of primary prophylacTic Implantable Cardioverter Defibrillators (EU-CERT-ICD)" is a modular research project to study… Expand
    ConditionsCoronary Artery Disease, Dilated Cardiomyopathy, Implantable Defibrillator User, (+1 more)

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 2,495 CITATIONS, ESTIMATED 44% COVERAGE

    Ventricular arrhythmias in Chagas disease.

    VIEW 4 EXCERPTS
    CITES BACKGROUND
    HIGHLY INFLUENCED

    Angiotensin Receptor Antagonists to Prevent Sudden Death in Heart Failure: Does the Dose Matter?

    VIEW 12 EXCERPTS
    CITES BACKGROUND & METHODS
    HIGHLY INFLUENCED

    Arrhythmias and heart failure.

    VIEW 4 EXCERPTS
    CITES RESULTS
    HIGHLY INFLUENCED

    FILTER CITATIONS BY YEAR

    2003
    2020

    CITATION STATISTICS

    • 171 Highly Influenced Citations

    • Averaged 174 Citations per year from 2017 through 2019

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 20 REFERENCES

    phylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction

    • AJ Moss, W Zareba, WJ Hall
    • N Engl J Med
    • 2002

    Sudden Cardiac Death-Heart Failure Trial (SCDHeFT)

    • GH Bardy, KL Lee, DB Mark
    • 2000
    VIEW 1 EXCERPT